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Abstract: Lipoprotein glomerulopathy is a pathological condition characterized by lipid accumulation in the glomerular capillaries 
that has been associated with the presence of rare mutants of apolipoprotein E (ApoE). We describe a 51-year-old Italian patient pre-
senting Type III hyperlipidemia and proteinuria in whom renal biopsy showed capillary ectasia and intraluminal lipid deposits, sug-
gesting the diagnosis of lipoprotein glomerulopathy. The patient, who had elevated plasma ApoE level, was found to be heterozygous 
for a mutation in ApoE (Arg150Cys), designated apoEMODENA. This mutation induces the formation of ApoE dimers that are detectable 
under non-reducing conditions. Treatment with hypolipidemic drugs did not result in a complete remission of the proteinuria and was 
accompanied by a slow but progressive worsening of renal function with the persistence of intracapillary lipid thrombi. The introduc-
tion of low-density lipoprotein aphaeresis combined with a more aggressive lipid lowering and antihypertensive therapy resulted in the 
remission of proteinuria and a substantial improvement of renal function. Switching from low-density lipoprotein aphaeresis to plasma 
filtration did not result in an equivalent control of renal damage. The patient died of intracranial hemorrhage during an acute episode of 
malignant hypertension.
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Introduction
Lipoprotein glomerulopathy (LPG) is a pathologi-
cal condition characterized by lipid accumulation 
in the glomerular capillaries and was first described 
by Saito et al in 1989.1 The histological hallmark of 
LPG is the presence of laminated thrombi consisting 
of lipid droplets within the lumina of dilated glom-
erular capillaries. Electron microscopy revealed that 
these lipid deposits show a layered texture resem-
bling fingerprints.2 These thrombi contain B and 
E  apolipoproteins that can be observed immunhis-
tochemically, suggesting the deposition of plasma 
lipoprotein particles.3 The plasma lipid profile of 
LPG patients is characterized by a variable elevation 
of very low-density lipoprotein and intermediate-
 density lipoprotein, resembling that reported in 
Type III hyperlipidemia associated with homozygos-
ity for apolipoprotein E2 isoform and elevation of 
plasma ApoE.2 Occasionally, renal lesions have been 
reported in the classic type III hyperlipidemia, but in 
these cases the histological features included glomer-
ulosclerosis associated with foam cells  accumulation.3 
LPG has been associated with the presence of rare 
mutants of apolipoprotein E characterized by amino 
acid substitutions (mostly located in the LDL bind-
ing domain) that predispose the deposition of ApoE/
ApoB containing lipoprotein within the glomerular 
 capillaries. These ApoE mutations have been reported 
mostly in Asian populations.4 Very few Caucasian 
cases of LPG patients have been reported.5,6
In this report, we extend the previous description7 
of a case of LPG by providing additional details 
on the follow-up, genetics, and biochemistry of the 
patient and her family. We describe an Italian patient 
with LPG with severe hyperlipidemia associated with 
an ApoE mutation that induces the formation of ApoE 
dimers.
case Report
A female 51-year-old Italian patient was referred to 
our outpatient clinic in February 2001 for proteinuria 
and microhaematuria. She reported a family history 
positive for intestinal neoplasia, diabetes, dyslipidemia 
and nephropathy. A deceased first grade cousin (sub-
ject III 7 in Fig. 1) had been under dialysis treatment of 
nephropathy of unknown etiology. Since the age of 45, 
the patient had been treated with inhibitors of platelet 
aggregation (lysine acetylsalicylate 160 mg/day) for 
vestibular symptoms. At 47, she started treatment with 
atorvastatin 10 mg/day for mixed hyperlipidemia (total 
cholesterol 375 mg/dL, triglycerides 305 mg/dL). At 
the first visit to our outpatient clinic, she showed nor-
mal renal function and normal fasting blood glucose; 
TAS, rheumatoid factor, C3 and C4 complement frac-
tions, Venereal Disease Research Laboratory (VDRL), 
serum immunofixation, plasma immunoglobulins 
were within the normal values. Markers for hepatitis 
B virus, hepatitis C virus, and human immunodefi-
ciency virus infections were negative. Routine labora-
tory parameters are reported in Table 1.
At physical examination, no xhantelasma, corneal 
arcus, or peripheral oedemas were present; BMI was 
21.6 kg/m2. On ultrasound examination, the kidneys 
showed regular structure and size. The arterial blood 
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Figure 1. pedigree of the family; the proband described in this case report is indicated by the arrow. A mutation in the Apoe gene was found (ApoeMoDeNA) 
in this subject. †This subject underwent dialytic treatment: however, clinical, pathological, or molecular data concerning the cause of renal failure are not 
available; *this subject developed a nephrotic syndrome; the kidney biopsy showed a minimal change glomerulonephritis, and no endoluminal thrombi 
were found. This subject was not a carrier of ApoeMoDeNA (see Table 1).
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pressure was 170/100 mmHg. Hypertension was 
treated by a combined therapy with ACE-Inhibitor, 
beta blocker, and calcium blocker (Ramipril 10 mg, 
Carvedilole 25 mg, and Amlodipine 10 mg/day).
First biopsy
Renal biopsy showed capillary ectasia accompanied 
by mesangiolysis. By methenamine silver- Periodic 
acid-Schiff stain (MPAS) the capillary walls appeared 
thickened with double contours.  Glomerular intralu-
minal thrombi appeared as weakly periodic acid-
Schiff (PAS)-positive deposits or pale blue deposits 
with Masson-trichrome; the lipid nature of the intralu-
minal deposits was demonstrated using Black 
Sudan and oil Red-O staining (Fig. 2 panel A–C; 
Fig. 4—shown in panels A–D). The  interstitium was 
characterized by diffuse fibroedema and tubular atro-
phy in the areas of fibrosis. Mild infiltration of inflam-
matory cells was present. The arterioles showed jalin 
deposits. Immunofluorescence examination showed 
that some deposits of IgM and C3 were found in the 
subendothelial space. Ultrastructure analysis con-
firmed the presence of thrombi in the lumina of the 
glomerular tufts showing finely vacuolated thrombi 
(Fig. 2 panel D). These features suggested the diag-
nosis of LPG. Oil Red O Staining and Black Sudan 
staining were used for lipid staining on 5-µm-thick 
frozen sections, 10% formalin fixation was applied. 
Paraffin embedded tissue sections were used for 
Masson trichrome, periodic acid Schiff, and MPAS 
staining. The specimen for electron microscopy was 
fixed with a solution of 4% formalin plus 1% glutar-
aldehyde in sodium phosphate buffer.
From February 2001 to December 2004, the 
patient was treated with hypolipemic drugs (atorvas-
tatin 40 mg and omega-3 fatty acids 3000 mg/day) 
and antihypertensive drugs (carvedilole 25 mg, 
amlodipine 10 mg, ramipril 10 mg, and irbesartan 
300 mg/day). This treatment resulted in a substantial 
reduction of plasma lipids and arterial blood pressure. 
 Proteinuria to creatinuria ratio was maintained below 
3 and renal function improved approaching the lower 
limits of normal values (Table 1).
Second biopsy
In early 2005, the patient showed a rapid deteriora-
tion of the arterial pressure control, a worsening of 
Table 1. Annual mean ± 1 standard deviation for laboratory and clinical data of the patient since presentation (2001) until 
2004.
normal values 2001 2002 2003 2004
Hemoglobin (g/dL) 12–16 11.9 ± 0.7 13.2 ± 0.1 13.3 ± 0.3 13.7 ± 0.2
proteinuria to creatinuria ratio ,0.3 2.86 ± 1.47 2.41 ± 0.83 2.75 ± 0.7  2.3 ± 0.6
Serum creatinine (mg/dL) 0.6–1.2 0.93 ± 0.06 1.20 ± 0.14 1.19 ± 0.12 1.32 ± 0.11
GFR according to Cockroft and  
Gault (mL/min)
50–90 69.2 ± 4.5 51.3 ± 6.0 51.2 ± 5.1 45.6 ± 3.8
Total serum protein (g/dL) 6–8 6.05 ± 0.49 6.40 ± 0.39 5.90 ± 0.65 6.10 ± 0.32
Serum albumin (g/dL) 4.02–4.76 3.14 ± 0.39 3.85 ± 0.22 3.44 ± 0.32 3.72 ± 0.48
Triglyceride (mg/dL) ,180  342 ± 190  351 ± 114  423 ± 121  231 ± 99
Cholesterol (mg/dL) 120–200  392 ± 73  283 ± 33  340 ± 15  296 ± 13
LDL (mg/dL) ,115  270 ± 48  167 ± 14  220 ± 14  180 ± 27
HDL (mg/dL) .39   63 ± 4   59 ± 1   57 ± 28   79 ± 13
Systolic arterial pressure (mmHg)  156 ± 6  137 ± 11  162 ± 10  156 ± 12
Diastolic arterial pressure (mmHg)   95 ± 4   92 ± 3   95 ± 7   95 ± 8
Figure 2. (A) capillaries in the glomerulus are distended by  lipoprotein 
thrombi (periodic acid Schiff staining ×400); (B) the enlarged  capillary 
lumina contain lipid material stained in black (Sudan Black stain-
ing ×400); (c) lipid thrombus in a capillary lumen (Red oil stain-
ing ×1000); (D) electron micrograph showing finely vacuolated intraluminal 
electrondense material (×2500).
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proteinuria and peripheral oedema associated with 
a deterioration of renal function (Fig. 3).  Creatinine 
was 1.9 mg/dL, albuminemia 2.9 g/dL, and pro-
teinuria 5 g/24 h. Blood pressure was elevated 
(AP 180/100 mmHg) and difficult to control despite 
the use of combined therapy with ACE inhibitors, 
calcium blocker, beta blocker and alpha blocker. The 
plasma lipid profile was characterized by a further 
increase in total cholesterol at 445 mg/dL (LDL-C 
318 mg/dL, HDL-C 88 mg/dL).
A second renal biopsy confirmed the pres-
ence of the lipid thrombi in the capillary lumina 
(apparently less abundant than in the first biopsy), 
a significant enlargement and proliferation of the 
mesangial area, segmental glomerular sclerosis, 
and expansion of interstitial fibrosis (Fig. 4: panels 
E–H).
The patient was treated with higher doses of lipid-
lowering and antihypertensive drugs, with addition of 
furosemide and cholestyramine. This treatment was 
associated with a reduction in arterial blood pressure, 
proteinuria, and plasma creatinine.  However, after 
3 months, the levels of proteinuria and creatinine 
were not normalized. Thus, LDL aphaeresis treat-
ment (heparin mediated extracorporeal low density 
lipoprotein precipitation, HELP) was started; this 
treatment regimen has been discussed elsewhere.7 
LDL aphaeresis was performed in three cycles over 
a period of 30 months (see Fig. 3 and Table 2). This 
treatment led to an acceptable clinical improvement. 
 Subsequently, as this treatment was not well-tolerated 
by the patient, so the frequency of LDL aphaeresis ses-
sions was reduced as depicted in Figure 3. However, 
relapses of proteinuria occurred after the LDL apha-
eresis discontinuation. In March 2008, for personal 
reasons the patient had to be referred to a center 
where HELP aphaeresis was not available. She was 
treated by plasma filtration (PF rheofilter, Fresenius 
AS TEC, Bad Homburg, Germany) until December 
2008 (shadowed area in Fig. 3). After this, proteinu-
ria and hypertension worsened, despite medical and 
aphaeretic treatment. The patient suddenly died of 
intracranial hemorrhage during an acute episode of 
malignant hypertension.
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Figure 3. The figure shows the frequency of LDL aphaeresis, the creatinine value, and the urine protein to creatinine ratio during treatment. The shadowed 
region of the panel indicates the period during which the patient switched from HELP aphaeresis to plasma filtration.
Lipoprotein glomerulopathy
Clinical Medicine Insights: Case Reports 2013:6 193
post-mortem biopsy
A renal biopsy was performed post-mortem at the time 
of liver explantation. The evaluation of the specimen 
showed nearly complete disappearance of glomeru-
lar intraluminal deposits as an absence of the typical 
capillary ectasia. (Fig. 4—available online: panels I, 
L, M and N). Tubular atrophy, fibrosis, and inflam-
matory cells infiltration rate were similar to those 
observed in the second biopsy.
DNA sequence analysis
The patient’s ApoE genotype was determined by 
direct sequencing. The sequence of exon 4 showed 
that the patient was homozygous for ε2 allele (Cys112 
and Cys158 of the mature protein).
In addition, the patient was found to be heterozy-
gous for a mutation in exon 4 of ApoE gene: c.502 
C.T (Arg150Cys in the mature protein). This muta-
tion was designated ApoEMODENA, after the city in 
which the patient was living. This mutation was 
screened in family members, who gave their consent 
for DNA analysis, and in 150 normolipidaemic con-
trol subjects. With the exception of the proband 
(subject III1 in Fig. 1 and Table 3), no carrier of the 
mutation was found.
plasma Apoe level and immunoblot
The plasma ApoE level in the proband was found 
to be increased (23 mg/dL vs. 3–10 mg/dL in nor-
molipaemic control subjects). ApoE immunob-
lot performed in non-reducing conditions showed 
the presence of a single band (34 kDa) in the con-
trol subject and two bands of 34 and ∼75 kDa in 
the proband. Under reducing conditions, only the 
34 kDa band was detected in the proband as in the 
control (Fig. 5).
Discussion
We described a subject with a long standing dys-
lipidemia who was referred to nephrologists for the 
presence of proteinuria and the clinical diagnosis of 
nephrotic syndrome. The association of proteinuria 
Figure 4. panels A–D, were obtained from the first biopsy; panels e–H were obtained from the second biopsy; panels I, L, M and n, were obtained from 
the post-mortem biopsy. panels A, e, I, D, H and N: (Masson’s trichrome ×400. panels B, F and L: MpAS staining, ×400. panels C, G and M periodic acid 
Schiff staining ×400.
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with the presence of lipid deposits in the capillary 
lumina (so-called lipoprotein thrombi) and a type III 
hyperlipidemia suggested a diagnosis of LPG.
LPG is characterized by disturbed remnant lipo-
protein catabolism, possibly resulting from altera-
tions in ApoE molecule and intravascular glomerular 
deposition of lipoprotein-containing thrombi. The 
involvement of ApoE in the pathogenesis of LPG 
is undeniable, but the mechanisms of its action in 
this disease remain unknown. A peculiar character-
istic of LPG is its strict predilection for the kidney. 
The increase in the intravascular concentration of 
lipoproteins carrying conformationally abnormal 
ApoE molecules during the ultrafiltration of fluid and 
micromolecules may predispose some individuals to 
the development of lipoprotein thrombi.8
This diagnosis was supported by the finding 
that the patient was homozygous for the E2 iso-
form and heterozygous for a mutation in ApoE 
(Arg150Cys). She also had elevated plasma level of 
ApoE. Interestingly, two different mutations of ApoE 
(both in heterozygous state) affecting the same amino 
acid residue at position 150 have been reported to 
be associated with LPG. These mutations include an 
Arg150Gly substitution (found in a patient homozy-
gous for E2 isoform)8 and an Arg150Pro substitution 
(found in a patient homozygous for E3 isoform).9 
Collectively, these three mutations (Arg150Gly, Arg-
150Pro, and Arg150Cys), which eliminate the argin-
ine residue at position 150, are expected to reduce the 
affinity of ApoE for the LDL receptor, which is located 
in the LDL-receptor binding domain.10 In our patient, 
this binding defect was expected to be amplified by the 
homozygosity for the ApoE2 isoform, which is known 
to have a reduced LDL receptor binding capacity.10
Notably, of the 12 mutations of ApoE associated 
with LPG reported thus far, six are located in the LDL 
receptor binding domain. This binding defect may 
Table 3. Genetic and lipidic data of relatives of the proband according to pedigree in Figure 1.
subject III.1 III.3 III.5 IV.1 IV.2 IV.3 IV.4
Apoe genotype ε2ε2 ε2ε3 ε3ε3 ε2ε3 ε2ε3 ε2ε3 ε2ε3
Apoe mutant allele W/M W/W W/W W/W W/W W/W W/W
Age (years) 51 59 53 29 29 33 15
TC (mg/dL) 331 198 226 158 160 196 139
TG (mg/dL) 227 201 172 72 93 83 54
HDL-C (mg/dL) 60 46 51 68 64 75 62
Abbreviations: W, wild-type allele; M, mutant allele (ApoeMoDeNA); TC, Total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol.
Table 2. Laboratory and clinical data of the patient before the starting HeLp aphaeresis, after 12 months of HeLp 
aphaeresis, and at exitus.
normal  
values
Before HeLp 
aphaeresis
After 12 months of 
HeLp aphaeresis
At exitus
Hemoglobin (g/dL) 12–16 10.2 11.6 9.8
proteinuria to creatinuria ratio ,0.3 2.1 0.3 10
Serum creatinine (mg/dL) 0.6–1.2 1.86 1.6 1.66
GFR according to Cockroft  
and Gault (mL/min)
50–90 31 41 35
Total serum protein (g/dL) 6–8 6.2 6.9 5
Serum albumin (g/dL) 4.02–4.76 3.7 4.1 2.8
Fibrinogen (mg/dL) 200–400 362 362 NA
Triglyceride (mg/dL) ,180 310 149 200
Cholesterol (mg/dL) 120–200 232 171 229
LDL (mg/dL) ,115 137 101 142
HDL (mg/dL) .39 59 83 74
ApoA-I (mg/L) 124 182 NA
Systolic/diastolic (mmHg) 
Arterial pressure (mmHg)
125/75 120/75 200/90
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be the basis for accumulation of very low-density 
 lipoprotein and intermediate-density lipoprotein in 
the plasma as the result of a defective LDL-receptor 
 mediated uptake of these lipoproteins by the liver, 
whereas the type of amino acid change may be respon-
sible for ApoE misfolding and possibly formation of 
lipoprotein thrombi in the glomerular capillaries. The 
mutation found in our patient, which introduced a 
novel cysteine residue, was expected to induce the for-
mation of ApoE dimers due to the formation of novel 
intermolecular disulphide bridges. This was demon-
strated by immunoblotting, which indicated that under 
reducing conditions, which is similar to the in vivo 
condition, ApoE dimers are formed. These may be 
homodimers containing two ApoEMODENA monomers 
or heterodimers containing one ApoEMODENA and one 
ApoE2 monomer. These dimers may render ApoE 
containing lipoproteins more unstable, facilitating 
their entrapment in the glomerular capillaries.
During the nine years of follow-up, the patient 
was treated for dyslipidemia, first with lipid-lowering 
drugs and subsequently with LDL aphaeresis, on the 
assumption that reduction of plasma lipids could have 
a beneficial effect on kidney function by reducing lipid 
thrombi formation. Treatment with hypolipidemic 
drugs did not result in remission of the proteinuria 
and was accompanied by a slow but progressive wors-
ening of renal function with the persistence of intra-
capillary lipid thrombi, increased interstitial fibrosis, 
and glomerulosclerosis, as documented by the second 
biopsy. Only the introduction of LDL aphaeresis and 
more aggressive lipid-lowering and antihypertensive 
therapies significantly improved the clinical picture 
with complete remission of proteinuria and substan-
tial recovery of renal function. Unfortunately, the 
compliance of the patient to LDL aphaeresis schedule 
progressively decreased over time, leading to discon-
tinuation of this treatment that was lately replaced by 
plasma filtration. This discontinuation and change of 
treatment prevented definite assessment of the long-
term impact of HELP aphaeresis on the progression 
of LPG. Nevertheless, our observations strongly indi-
cate that LDL aphaeresis treatment should be con-
sidered in the rare cases of LPG and is in keeping 
with a previous study where an alternative aphaeretic 
approach had been adopted. Xin et al11 reported that 
protein A immunoabsorption had beneficial effects in 
a patient with LPG with a disappearance of intralumi-
nal thrombi following treatment, while discontinua-
tion of this treatment was associated with a relapse of 
proteinuria and deterioration of kidney function.
In conclusion, we described a Caucasian 
patient with LPG associated with an ApoE mutant 
(ApoEMODENA). Hypolipidemic treatment achieved 
partial control of the condition that significantly 
improved only after HELP aphaeresis. However, we 
are aware that the beneficial effect of HELP aphaer-
esis on LPG derived from the description of a single 
case must be substantiated by a prospective clinical 
trial, requiring a coordinated international effort due 
to the rarity of LPG.
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